期刊文献+

靶向人表皮生长因子受体的抗体药物研究进展 被引量:1

原文传递
导出
摘要 人表皮生长因子受体(EGFR)是肿瘤治疗,尤其是肿瘤的靶向治疗中重要的靶标。以其为靶点开发的抗体药物已经广泛用于癌症的治疗,尤其是转移性结直肠癌、头颈部癌症等的治疗。本文综述了靶向EGFR的抗体药物相关研究背景及最新研究进展,将为开发针对该靶点新型抗体提供参考。
出处 《现代免疫学》 CAS CSCD 北大核心 2015年第2期172-174,144,共4页 Current Immunology
基金 国家"863"计划(2014AA021004) 国家"973"计划(2010CB833605) 国家自然科学基金(81330061) 国家"重大新药创新"计划(2013ZX09101021)
  • 相关文献

参考文献27

  • 1吴炜霖,仲人前.人源化抗体的演进发展及应用现状[J].现代免疫学,2009,29(4):337-340. 被引量:2
  • 2Tomas A,Futter CE,Eden ER.EGF receptor trafficking:consequences for signaling and cancer[J].Trends Cell Biol,2014,24:26-34.
  • 3Kozer N,Barua D,Henderson C,et al.Recruitment of the adaptor protein Grb2to EGFR tetramers[J].Biochemistry,2014,53:2594-2604.
  • 4Yarden Y.The EGFR family and its ligands in human cancer.signalling mechanisms and therapeutic opportunities[J].Eur J Cancer,2001,37:S3-8.
  • 5Baselga J.The EGFR as a target for anticancer therapy-focus on cetuximab[J].Eur J Cancer,2001,37:S16-22.
  • 6Goldstein NI,Prewett M,Zuklys K,et al.Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model[J].Clin Cancer Res,1995,1:1311-1318.
  • 7Wu X,Rubin M,Fan Z,et al.Involvement of p27KIP1in G1arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody[J].Oncogene,1996,12:1397-1403.
  • 8Gerdes CA,Nicolini VG,Herter S,et al.GA201(RG7160):a novel,humanized,glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab[J].Clin Cancer Res,2013,19:1126-1138.
  • 9阿地力江.伊明,葛海良,张惠珍,王颖,张勇,王树军,拉莱.苏祖克.C225单用及与DDP联用对HeLa细胞的抑制作用与机制研究[J].现代免疫学,2008,28(4):298-304. 被引量:2
  • 10Capdevila J,Elez E,Macarulla T,et al.Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment[J].Cancer Treat Rev,2009,35:354-363.

二级参考文献16

  • 1陈立慧,宋海峰,刘秀文.治疗性人源化单克隆抗体研究进展[J].中国新药杂志,2004,13(7):590-594. 被引量:10
  • 2葛彦,张学光.人源化抗体研制策略分析及应用研究[J].国外医学(免疫学分册),2004,27(5):271-274. 被引量:10
  • 3钱军,秦叔逵.以表皮生长因子受体为靶点的抗癌新药——C225[J].中国实用内科杂志,2005,25(8):676-679. 被引量:14
  • 4张爱华,余模松.噬菌体抗体库技术[J].国际生物制品学杂志,2006,29(1):13-16. 被引量:6
  • 5刘新垣.癌症靶向治疗的最新进展[J].中华肿瘤防治杂志,2006,13(18):1361-1364. 被引量:19
  • 6[2]Baselga J.The EGFR as a target for anticancer therapy-focus on cetuximab[J].Eur J Cancer,2001;37 Suppl 4:S16-22.
  • 7[3]Ciardiello F,Tortora G.A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor[J].Clin Cancer Res,2001,7:2958-2970.
  • 8[4]Sung FL,Poon TC,Hui EP,et al.Antitumor or effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma a cells[J].In Vivo,2005,19(1):237-245.
  • 9[5]Huang SM,Bock JM,Harari PM.Epidermal growth factor receptor blockade with C225 modulates proliferation,apoptosis,and radiosensitivity in squamous cell carcinomas of the head and neck[J].Cancer Res,1999,59(8):1935-1940.
  • 10[6]Prewett M,Rockwell P,Rockwell RF,et al.The biologic effects of C225,a chimeric monoclonal antibody to the EGFR,on human prostate carcinoma[J].J Immunother Emphasis Tumor Immunol,1996;19(6):419-427.

共引文献2

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部